Exploring strategies for targeting oncogenic beta-catenin

The discovery of an inhibitor that acts at, or downstream of beta-catenin would not only be a valuable tool for exploring the role of WNT signalling in cancer biology, but importantly would address the high unmet need for better treatment options for colorectal cancer and breast cancer sub-types dependent on WNT-signalling. The project outlined here would further our biological understanding of whether transient or allosteric pockets in Beta-catenin can be targeted to displace binding of BCL9/9L an essential co-activator of oncogenic beta-catenin activity.